Harrington, D.J., Underwood, S., Morse, C., Shearer, M.J., Tuddenham, E.G. and Mumford, A.D. (2005) Pharmacodynamic resistance to warfarin associated with Val66Met Substitution in Vitamin K epoxide reductase complex 1. Thrombosis & Haemostasis, 93, 23-26.

has been cited by the following article:

• TITLE: Combined effect of CYP2C9 and VKORC1 polymorphisms on warfarin maintenance dose in Omani patients

  AUTHORS: Anil Pathare, Salam Alkindi, Shoaib Al Zadjali, Rhea Misquith, Fauzia Wasim, Tsouria Berbar, Andras Paldi, Rajagopal Krishnamoorthy

  KEYWORDS: CYP2C9; CYP4F2; VKORC1; Pharmacogenetics; Polymorphism; Omani

  JOURNAL NAME: Open Journal of Genetics, Vol.2 No.4, December 31, 2012

  ABSTRACT: Excepting host genetic factors, other influences on the pharmacokinetic and pharmacodynamic behavior of warfarin are subject to variations during the treatment despite attempts to stabilize the INR. In 214 Omani patients on warfarin therapy, we evaluated the extent of influence of known genetic predictors of warfarin dose variability, namely CYP2C9, CYP4F2 and VKORC1 gene polymorphisms in a genetically heterogeneous patient population. When patients were stratified according to their daily warfarin maintenance dose (to maintain INR between 2 and 3) into “low dose” (sensitive), “medium dose” (intermediate) and “high dose” (resistance) groups, overall, seven patients with three or four mutant alleles fell in the sensitive group and consequently 25% (7 out of 28) of at risk patients for over anticoagulation can be recognized by prospective pharmacogenetic testing in this patient population. Pre-prescription genotyping of these loci prior to therapy initiation will therefore benefit a small fraction of this population.